Compugen Ltd
Closed
2.37 -1.25
Overview
Share price change
24h
Min
2.38
Max
2.41
Income | 663K -7M |
|---|---|
Sales | 426K 2.6M |
P/E Sector Avg | 6.324 57.002 |
EPS | -0.07 |
Profit margin | -269.254 |
Employees | 75 |
EBITDA | 665K -7M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +107.47% upside |
Next Earnings | 9 Nov 2026 |
|---|
Market Cap | -3.8M 221M |
|---|---|
Previous open | 3.62 |
Previous close | 2.37 |
Compugen Ltd Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Compugen Ltd Forecast
Price Target
By TipRanks
107.47% upside
12 Months Forecast
Average 5 USD 107.47%
High 6 USD
Low 4 USD
Based on 3 Wall Street analysts offering 12 month price targets forCompugen Ltd - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Compugen Ltd
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
